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OBJECTIVE: Fesoterodine is an effective, safe, and well-
tolerated treatment indicated for patients with overactive bladder
(OAB). The aim of this study was to assess, from a societal
perspective, the cost-effectiveness of one-year treatment with fes-
oterodine 4 mg and 8 mg compared with tolterodine ER 4mg.
METHODS: We developed a health economic model simulating
the treatment outcomes of OAB patients initiating therapy. Dis-
continuation, efﬁcacy, and health-related quality of life (HRQL)
were based on the results of a 12-week multinational randomised
clinical trial extrapolated to one year. Probabilities and costs of
OAB-related co-morbidities, medical and incontinence pad costs,
and cost of lost time from work were also included in the model
and taken from published literature. Prices of fesoterodine 4 and
8 mg and tolterodine are taken from the public data-base; $1.98,
$2.35 and $2.10, respectively ($1 = 6.42kr). Treatment response
is deﬁned as resolution of incontinence measured by self-reported
diary entries. Responders and non-responders were assigned a
gain in quality-adjusted life years (QALYs) based on the results of
the King’s Health Questionnaire, a HRQL instrument validated
in patients with OAB collected during the trial. Treatment dis-
continuers are assigned no QALY-gain. Sensitivity analysis of key
parameters was also performed. All costs are expressed in 2007
Swedish Kr. RESULTS: In the base case, fesoterodine 4 mg and
8 mg are more effective than tolterodine with QALY gains of
0.01008 and 0.01116 versus 0.00947, and have lower overall
costs ($6.918 and $6.549 versus $7.255). These results indicate
that treatment with fesoterodine 4 mg or 8 mg is a cost-saving
treatment strategy compared with tolterodine. Results were
robust to changes in treatment responder rates and OAB-related
co-morbidity rates. As most models, results were more sensitive
to treatment-associated utility values. CONCLUSION: Our
results suggest that at the current prices, fesoterodine 4 mg and
fesoterodine 8 mg provide additional health beneﬁts at lower
costs compared to tolterodine.
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OBJECTIVE: To investigate the cost-effectiveness of immuno-
suppressive regimens in renal transplant recipients in Germany.
METHODS: A micro-simulation model was built comparing
immunosuppressive regimens based on cyclosporine, everolimus,
sirolimus, and tacrolimus in renal transplants. Within the model,
mean costs per patient as well as incremental costs per life year
gained and per year with functioning graft were assessed from
the perspective of the German statutory health insurance (SHI).
The evaluation was performed for a two and a ten year time
horizon. Effectiveness data up to two years was derived from a
meta-analysis. Starting from year three, the model was populated
with extrapolated clinical data, mainly originating from a patient
register, which was equally implemented for all regimens consid-
ered. Cost data was estimated based on relevant tariff works and
literature. Base year for costing was 2007. To test the robustness
of the model, probabilistic sensitivity analyses were conducted.
RESULTS: Over the 2-year period, mean total costs per patient
amount to €25,248, €29,444, €33,482, and €49,985 for siroli-
mus, cyclosporine, everolimus, and tacrolimus, respectively.
Focusing on the costs per life year gained, sirolimus dominates
everolimus. The incremental cost-effectiveness ratio of cyclospo-
rine and tacrolimus compared to sirolimus is €209,800 and
€1,902,846, respectively. Regarding the costs per year with func-
tioning graft gained, sirolimus dominates all other regimens con-
sidered by showing better effects at lower costs. Over the 10-year
time frame, mean total costs per patient were €97,678, €108,647,
€120,694, and €183,936 for sirolimus, cyclosporine, everolimus,
and tacrolimus, respectively. Sirolimus also shows the best results
in survival and time with functioning graft, thus dominating the
three alternatives. The model is robust to variations of all param-
eters. CONCLUSION: Over both the 2-year and the 10-year
time horizon, sirolimus-based immunosuppression represents a
cost-effective option in renal transplant recipients in Germany.
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OBJECTIVE: To review the methodologies of published articles
describing full economic evaluations of tolterodine, an antimus-
carinic agent used to treat overactive bladder (OAB).
METHODS: A search of MEDLINE and EMBASE using the
search terms “tolterodine” and “cost” or “economic” was con-
ducted (1990–December 2007). English-language citations with
abstracts were reviewed. Publications reporting an original
formal economic evaluation of tolterodine compared with 1
alternative were selected for inclusion. RESULTS: Of the 172
citations identiﬁed from the search, only 12 met the inclusion
criteria. All studies adopted a payor and/or patient perspective.
Two were cost analyses based on retrospective databases. Ten
used modeling, including 6 cost-effectiveness, 2 cost utility, and
2 cost minimization. Five of the 8 cost-effectiveness/utility
studies modeled treatment outcomes using patient-level clinical
trial data, whereas the remaining 3 used published clinical trial
data and/or expert opinion. 4 of the modeling studies employed
Markov methods, 5 used a decision-analytic method, and 1 was
a probabilistic disease model based on the expected distribution
of patient symptoms. All studies compared different formulations
of tolterodine and oxybutynin, sometimes alongside other com-
parators. Only three of the modeling studies included the possi-
bility of drug switching or titration. With respect to health care
resource utilization, all modeling studies included antimuscarinic
drug costs, and most included costs of physician visits and incon-
tinence pads. Costs of laundry, surgical procedures, staff and
direct overhead, behavioral therapy, laboratory procedures or
diagnostic tests, OAB-related comorbidities, and absenteeism
were not consistently considered. Primary effect measures varied;
incontinence was the most commonly used. CONCLUSIONS:
Important differences in design, modeling methodology, assump-
tions, and selection of cost and effects can be found across
published economic analyses of tolterodine. Future analyses of
new antimuscarinics should comprehensively assess direct
medical and indirect productivity costs, including OAB-related
comorbidities and the beneﬁts of therapy in terms of quality-
adjusted life-years gained.
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